Expiration date: 05/2025

Active ingredient

• famciclovir (famciclovir)

Composition

Each film-coated tablet, 125 mg, contains:

active ingredient: famciclovir-125.00 mg;

excipients: pre-gelatinized starch-18.70 mg, microcrystalline cellulose-11.00 mg, croscarmellose sodium-10.20 mg, sodium lauryl sulfate-1.70 mg, colloidal anhydrous silicon dioxide-1.70 mg, stearic acid-1.70 mg;

film coating: Opadray white OY-S-28924 (hypromellose-5sR-1.87 mg, titanium dioxide-1.02 mg, hypromellose-15sR-0.62 mg, macrogol-4000-0.37 mg, macrogol-6000-0.37 mg) - 4.25 mg.

Pharmacological action

An antiviral agent. After oral administration, famciclovir is rapidly converted in vivo to penciclovir, which has in vivo and in vitro activity against human herpes viruses, including Varicella zoster virus and Herpes simplex types 1 and 2, as well as Epstein-Barr virus and cytomegalovirus.

Penciclovir enters virus-infected cells, where, under the action of viral thymidine kinase, it is rapidly converted to monophosphate, which in turn, with the participation of cellular enzymes, is converted to triphosphate. Penciclovir triphosphate is present in virus-infected cells for more than 12 hours, suppressing viral DNA synthesis and virus replication. The half-life of penciclovir triphosphate in cells affected by Varicella zoster, Herpes simplex, is 9, 10 and 20 hours, respectively. The concentration of penciclovir triphosphate in uninfected cells does not exceed the minimum detectable, therefore, in therapeutic concentrations, penciclovir does not affect uninfected cells.

Penciclovir is active against recently discovered acyclovir-resistant strains of the Herpes simplex virus with altered DNA polymerase.

Famciclovir significantly reduces the intensity and duration of postherpetic neuralgia in patients with herpes zoster.

In a placebo-controlled study in patients with immunodeficiency due to HIV infection, famciclovir at a dose of 500 mg 2 times / day reduced the number of days of isolation of the Herpes simplex virus (both with and without clinical manifestations).

Indications

Infections caused by Varicella zoster virus (shingles, including shingles with ocular complications); infections caused by Herpes simplex virus (primary infection, exacerbation of chronic infection, suppression of recurrent infection).